Bavarian Nordic to Report New PROSTVAC® Clinical Data at the American Society of Clinical Oncology Annual Meeting
KVISTGAARD, Denmark, May 18, 2012 - Bavarian
Nordic A/S (OMX: BAVA) today announced that new interim data from
an ongoing, Phase 2 randomized trial of the Company's PROSTVAC®
therapeutic cancer vaccine when used in combination with
Quadramet® (samarium-153 EDTMP), a commercially available
skeletal-targeted radiopharmaceutical, will be presented as a
poster during the 2012 American Society of Clinical Oncology (ASCO)
Annual Meeting in Chicago, Illinois on June 2, 2012.
Bavarian Nordic's PROSPECT, a single global, randomized,
double-blind, placebo-controlled Phase 3 study of PROSTVAC® in
prostate cancer patients with metastatic disease who have failed
hormone therapy is also the subject of a "Trials in Progress"
abstract, which is designed to provide an opportunity for members
of the research community to present ongoing trials, foster
collaboration, and discuss correlatives and novel trial
designs.
Abstract titles and presentation times are provided below.
- "Interim analysis of a phase 2 randomized clinical trial of
Samarium-153 (Sm-153) with or without PSA-TRICOM vaccine in
metastatic castration resistant prostate cancer (mCRPC) after
docetaxel", abstract number 2526, Poster Discussion Session,
Developmental Therapeutics - Clinical Pharmacology and
Immunotherapy from 8:00 AM to 12:00 PM CT on Saturday June 2,
2012.
- "Prospect: A Randomized, Double-blind, Phase 3 Efficacy Trial
of PROSTVAC®", abstract number TPS4699, General Poster Session,
Genitourinary Cancer from 8:00 AM to 12:00 PM CT on Sunday June 3,
2012.
Bavarian Nordic will also be hosting a PROSTVAC® update and
reception on Monday, June 4, 2012 in Chicago, Illinois. The
principal investigators for the PROSPECT trial, James L. Gulley,
M.D., Ph.D., Director of the Clinical Trials Group at the
Laboratory of Tumor Immunology and Biology at the National Cancer
Institute (NCI), and Philip Kantoff M.D., Professor of Medicine at
Harvard Medical School, will be joined by members of the Company's
senior management team to discuss this next-generation prostate
cancer vaccine. To register for this event, or for more
information, please contact Mette Buhl of Bavarian Nordic via email
at mette.buhl@bavarian-nordic.com or by phone at +45 33 28 83
00.
Contact:
Anders Hedegaard, President & CEO.
Phone: +45 23 20 30 64
